CVS Health Study Finds GLP-1 Medical Savings Do Not Fully Offset Drug Costs at Current Prices

An analysis of Aetna claims found lower medical spending among GLP-1 users, but CVS modeled a roughly $350 monthly net price to offset added drug costs.

Published
Share

CVS Health says the medical savings associated with GLP-1 treatment have not been large enough to cover the drugs’ additional pharmacy costs at current prices. The finding comes from an analysis of Aetna insurance claims that linked use of the medicines to fewer hospital visits and lower spending on medical care, but not to a reduction in total health spending after drug costs were included.

The company estimates that a net drug price of approximately $350 a month, sustained over three years, would have brought the medical savings and added pharmacy spending into balance for the population it studied. That is a modeled break-even price for the group, not a price that would make GLP-1 treatment cost-neutral for every person or every health plan.

The results add a financial dimension to the debate over access to medicines used for diabetes, obesity and other conditions. Their clinical benefits are an important part of the decision, but employers and insurers must also account for prescription spending that arrives well before all potential health benefits can be measured.

Lower medical spending did not erase higher pharmacy bills

CVS examined anonymized claims from commercially insured Aetna members whose plans were fully insured, meaning the insurer bore the risk of paying their medical claims. The study included people who began GLP-1 treatment in index years from 2023 through 2025, with follow-up lasting up to three years. Researchers matched users to people not taking the drugs based on age, existing health conditions, previous health care use, and earlier medical and pharmacy spending.

That comparison is central to the findings. People prescribed a GLP-1 can differ from non-users in ways that affect their health care costs, so comparing all users with all non-users would not provide a meaningful measure of how spending changes. Matching addresses several measurable differences, although it does not eliminate factors that claims data cannot fully capture.

CVS reported better clinical outcomes and less hospital use among GLP-1 users than among their matched peers. Medical spending was also lower. The additional pharmacy bills were larger than those savings, leaving the overall financial result unfavorable at prevailing net drug prices. The company said the pattern depended on underlying health risk and on how long patients continued therapy.

Additional figures shared with Reuters illustrate the gap. The news agency reported that, over three years, medical bills were about $9,400 lower per person in the comparison while prescription spending was roughly $13,300 higher, producing an added net cost of approximately $3,900. Those figures are attributed to Reuters’ reporting on the analysis rather than independently recalculated by MarketReview from the underlying claims.

The evidence should not be read as a randomized trial demonstrating that the medicine itself caused every observed reduction in hospital or emergency care. It is an observational analysis of insured patients. Nor is the three-year spending comparison a complete accounting of lifetime medical value: some benefits may take longer to appear, while some expenses or treatment interruptions can change the result along the way.

Why CVS models a $350 monthly break-even price

In its GLP-1 white paper, CVS puts the modeled net price at about $350 a month over the three-year observation period. The threshold is intended to identify where the increased cost of the prescription would be matched by lower medical spending in the study population. It is not a recommended retail price, a patient copay or a guarantee of savings for an individual employer.

Baseline health risks matter because the medical spending that can potentially be avoided is not the same for everyone. A patient already at high risk of hospitalization may have more near-term costs that treatment can help reduce than a younger person with fewer diagnosed conditions. A single break-even price therefore conceals substantial variation across indications and patient populations.

CVS also separated people who started treatment from those whose filled prescriptions covered at least 80% of days during follow-up. That measure of adherence matters to both sides of the calculation. Continued use may be associated with better outcomes, but the plan also keeps paying for the medicine. A health plan cannot assume that savings associated with sustained use will automatically appear among everyone who fills an initial prescription.

An earlier Employee Benefit Research Institute analysis estimated net prices of about $617 to $766 for a 30-day GLP-1 supply. That offers a useful indication of the cost pressure facing employment-based coverage, although EBRI’s estimates and CVS’s modeled threshold come from different analyses and should not be treated as identical measures for every drug, dosage or contract.

Price is only one assumption in the economics. The mix of patients taking a drug, the share remaining on treatment and the time horizon used to count avoided medical care can change the result. Aetna’s fully insured claims also do not necessarily reproduce what a self-funded employer would experience with a different workforce, benefit design or negotiated pharmacy price.

Coverage decisions remain a separate question

For employers deciding whether to cover GLP-1 medicines for weight management, the study provides a cost benchmark rather than a yes-or-no coverage rule. The research covers patients with different medical indications. It does not establish that the $350 figure applies specifically to obesity treatment alone, or that medical value can be judged entirely by whether an insurer breaks even within three years.

Affordability concerns were already affecting benefit decisions. An August survey released by CVS Caremark and Employee Benefit News found that 77% of employers surveyed regarded the high cost of GLP-1 coverage as a concern, while 80% had limited coverage for weight loss or were considering limits. Those survey responses describe employers’ reported concerns, not the spending outcomes of the Aetna patients in the new research.

CVS Caremark has also been changing access to the medicines as it negotiates pharmacy benefits. It said in May that Zepbound would return as an additional preferred option on its common commercial formularies from October 1, 2026. Employers using those templates still have discretion over their own coverage decisions. That is an important distinction between a pharmacy benefit manager’s formulary option and a commitment by an individual plan to pay for treatment.

Government programs illustrate how different the price and coverage arrangements can be. Under the Centers for Medicare & Medicaid Services’ GLP-1 Bridge, eligible Medicare beneficiaries can obtain certain weight-management medicines with a $50 monthly copay, while participating manufacturers provide eligible drugs at a $245 net monthly price. The program operates outside the normal Part D benefit payment flow. Neither the beneficiary’s copay nor that demonstration’s negotiated price is directly comparable to the commercial break-even figure modeled by CVS.

The study also leaves a longer-term question open. Earlier intervention could prevent medical problems beyond the follow-up period, but projections over decades require assumptions that are not established by several years of claims. Conversely, broader prescribing to people at lower immediate medical risk may make short-term offsets harder to achieve even if treatment benefits patients.

CVS said Chief Medical Officer Amy Compton-Phillips would discuss the findings at the HLTH industry conference in Las Vegas on November 15. For coverage discussions, the immediate finding is narrower than a verdict on the medicines themselves: among the insured patients CVS studied, the health care savings were meaningful, but current net drug costs still exceeded them.

Monica

About the author

Monica Stankowski

Market Analyst

Monica Stankowski analyzes markets using fundamental, valuation and price-based evidence. Her work compares competing explanations, identifies the factors that may change an outlook and treats market conclusions as informed analysis rather than guaranteed predictions.

View author profile